|
1
|
Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway.
|
Nature
|
2013
|
6.53
|
|
2
|
Clinicopathologic correlates of solitary fibrous tumors.
|
Cancer
|
2002
|
5.96
|
|
3
|
Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function.
|
Cancer Res
|
2010
|
4.71
|
|
4
|
BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma.
|
Clin Cancer Res
|
2013
|
4.28
|
|
5
|
Causes, consequences, and remedies for growth-induced solid stress in murine and human tumors.
|
Proc Natl Acad Sci U S A
|
2012
|
2.66
|
|
6
|
Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype.
|
Clin Cancer Res
|
2009
|
2.62
|
|
7
|
Pancreatic ductal adenocarcinoma: is there a survival difference for R1 resections versus locally advanced unresectable tumors? What is a "true" R0 resection?
|
Ann Surg
|
2013
|
2.26
|
|
8
|
Incidental pancreatic cysts: do we really know what we are watching?
|
Pancreatology
|
2010
|
2.22
|
|
9
|
Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment.
|
J Clin Oncol
|
2011
|
2.13
|
|
10
|
A single heteroclitic epitope determines cancer immunity after xenogeneic DNA immunization against a tumor differentiation antigen.
|
J Immunol
|
2003
|
1.81
|
|
11
|
Implications of incidentally discovered, nonfunctioning pancreatic endocrine tumors: short-term and long-term patient outcomes.
|
Arch Surg
|
2011
|
1.78
|
|
12
|
FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience.
|
Oncologist
|
2013
|
1.76
|
|
13
|
851 resected cystic tumors of the pancreas: a 33-year experience at the Massachusetts General Hospital.
|
Surgery
|
2012
|
1.68
|
|
14
|
Vascular and biliary variants in the liver: implications for liver surgery.
|
Radiographics
|
2008
|
1.62
|
|
15
|
Branch duct intraductal papillary mucinous neoplasms: does cyst size change the tip of the scale? A critical analysis of the revised international consensus guidelines in a large single-institutional series.
|
Ann Surg
|
2013
|
1.58
|
|
16
|
Targeting ALDH(bright) human carcinoma-initiating cells with ALDH1A1-specific CD8⁺ T cells.
|
Clin Cancer Res
|
2011
|
1.54
|
|
17
|
Limitations of ampullectomy in the treatment of nonfamilial ampullary neoplasms.
|
Ann Surg Oncol
|
2005
|
1.48
|
|
18
|
Metastatic tumors in the pancreas in the modern era.
|
J Am Coll Surg
|
2010
|
1.45
|
|
19
|
Improved contemporary surgical management of insulinomas: a 25-year experience at the Massachusetts General Hospital.
|
Ann Surg
|
2008
|
1.45
|
|
20
|
Evolution of the Whipple procedure at the Massachusetts General Hospital.
|
Surgery
|
2012
|
1.40
|
|
21
|
Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma.
|
Clin Cancer Res
|
2014
|
1.33
|
|
22
|
CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems.
|
Vaccine
|
2004
|
1.25
|
|
23
|
Redundant and alternative roles for activating Fc receptors and complement in an antibody-dependent model of autoimmune vitiligo.
|
Immunity
|
2002
|
1.19
|
|
24
|
Surgery for small and asymptomatic branch-duct IPMNs.
|
Ann Surg
|
2014
|
1.13
|
|
25
|
A nomogram to predict long-term survival after resection for intrahepatic cholangiocarcinoma: an Eastern and Western experience.
|
JAMA Surg
|
2014
|
1.11
|
|
26
|
N0/N1, PNL, or LNR? The effect of lymph node number on accurate survival prediction in pancreatic ductal adenocarcinoma.
|
J Gastrointest Surg
|
2012
|
1.09
|
|
27
|
Gallbladder lesions identified on ultrasound. Lessons from the last 10 years.
|
J Gastrointest Surg
|
2011
|
1.06
|
|
28
|
Trends in presentation and survival for gallbladder cancer during a period of more than 4 decades: a single-institution experience.
|
Arch Surg
|
2009
|
1.06
|
|
29
|
Cytology adds value to imaging studies for risk assessment of malignancy in pancreatic mucinous cysts.
|
Ann Surg
|
2011
|
1.05
|
|
30
|
Understanding hospital readmissions after pancreaticoduodenectomy: can we prevent them?: a 10-year contemporary experience with 1,173 patients at the Massachusetts General Hospital.
|
J Gastrointest Surg
|
2013
|
1.03
|
|
31
|
Another dimension in magnetic resonance cholangiopancreatography: comparison of 2- and 3-dimensional magnetic resonance cholangiopancreatography for the evaluation of intraductal papillary mucinous neoplasm of the pancreas.
|
J Comput Assist Tomogr
|
2009
|
1.00
|
|
32
|
Updated long-term outcomes and prognostic factors for patients with unresectable locally advanced pancreatic cancer treated with intraoperative radiotherapy at the Massachusetts General Hospital, 1978 to 2010.
|
Cancer
|
2013
|
0.99
|
|
33
|
Invasive intraductal papillary mucinous carcinomas of the pancreas: predictors of survival and the role of lymph node ratio.
|
Ann Surg
|
2010
|
0.98
|
|
34
|
Multi-institutional Validation Study of the American Joint Commission on Cancer (8th Edition) Changes for T and N Staging in Patients with Pancreatic Adenocarcinoma.
|
Ann Surg
|
2016
|
0.98
|
|
35
|
Recurrence after operative management of intrahepatic cholangiocarcinoma.
|
Surgery
|
2013
|
0.96
|
|
36
|
Why do patients with low-grade soft tissue sarcoma die?
|
Ann Surg Oncol
|
2008
|
0.96
|
|
37
|
GeLC-MRM quantitation of mutant KRAS oncoprotein in complex biological samples.
|
J Proteome Res
|
2012
|
0.95
|
|
38
|
PDGFRα up-regulation mediated by sonic hedgehog pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutation.
|
Oncotarget
|
2014
|
0.94
|
|
39
|
High performing whipple patients: factors associated with short length of stay after open pancreaticoduodenectomy.
|
J Gastrointest Surg
|
2014
|
0.92
|
|
40
|
Preoperative platelet count and survival prognosis in resected pancreatic ductal adenocarcinoma.
|
World J Surg
|
2008
|
0.92
|
|
41
|
Does the mechanism of lymph node invasion affect survival in patients with pancreatic ductal adenocarcinoma?
|
J Gastrointest Surg
|
2009
|
0.87
|
|
42
|
Blocking the formation of radiation-induced breast cancer stem cells.
|
Oncotarget
|
2014
|
0.87
|
|
43
|
Mechanisms of immunization against cancer using chimeric antigens.
|
Mol Ther
|
2008
|
0.85
|
|
44
|
Patterns of Recurrence After Resection of IPMN: Who, When, and How?
|
Ann Surg
|
2015
|
0.83
|
|
45
|
Treatment of Locally Advanced Pancreatic Ductal Adenocarcinoma.
|
Dig Surg
|
2016
|
0.83
|
|
46
|
Early Drain Removal--The Middle Ground Between the Drain Versus No Drain Debate in Patients Undergoing Pancreaticoduodenectomy: A Prospective Validation Study.
|
Ann Surg
|
2015
|
0.82
|
|
47
|
Evolution of studies of HLA class I antigen processing machinery (APM) components in malignant cells.
|
Clin Transpl
|
2013
|
0.81
|
|
48
|
Emerging BRAF inhibitors for melanoma.
|
Expert Opin Emerg Drugs
|
2013
|
0.80
|
|
49
|
Intraductal papillary mucinous neoplasms: does a family history of pancreatic cancer matter?
|
Pancreatology
|
2012
|
0.80
|
|
50
|
Microsatellite instability in gallbladder carcinoma.
|
Virchows Arch
|
2015
|
0.80
|
|
51
|
Does Size Matter in Pancreatic Cancer?: Reappraisal of Tumour Dimension as a Predictor of Outcome Beyond the TNM.
|
Ann Surg
|
2017
|
0.79
|
|
52
|
Targeting the MAGE A3 antigen in pancreatic cancer.
|
Surgery
|
2012
|
0.78
|
|
53
|
Strategies to overcome immune ignorance and tolerance.
|
Semin Cancer Biol
|
2002
|
0.78
|
|
54
|
Short-term outcomes in obese patients after colectomy for adenocarcinoma at a bariatric center.
|
J Gastrointest Surg
|
2012
|
0.78
|
|
55
|
Pancreatic neuroendocrine tumors with involved surgical margins: prognostic factors and the role of adjuvant radiotherapy.
|
Int J Radiat Oncol Biol Phys
|
2012
|
0.77
|
|
56
|
Intraductal Papillary Mucinous Neoplasm of the Pancreas: Current State of the Art and Ongoing Controversies.
|
Ann Surg
|
2016
|
0.76
|
|
57
|
Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.
|
J Natl Compr Canc Netw
|
2017
|
0.76
|
|
58
|
Reply to letter: "Retrospective studies and pancreatic adenocarcinoma: how far can we backdate?".
|
Ann Surg
|
2015
|
0.75
|
|
59
|
In response to Birgir Gudjonsson, MD.
|
Surgery
|
2013
|
0.75
|
|
60
|
Case records of the Massachusetts General Hospital. Case 19-2010. A 35-year-old man with adenocarcinoma of the cecum.
|
N Engl J Med
|
2010
|
0.75
|
|
61
|
Development and Validation of a Multi-Institutional Preoperative Nomogram for Predicting Grade of Dysplasia in Intraductal Papillary Mucinous Neoplasms (IPMNs) of the Pancreas: A Report from The Pancreatic Surgery Consortium.
|
Ann Surg
|
2016
|
0.75
|
|
62
|
Corrigendum: Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer.
|
Nature
|
2015
|
0.75
|
|
63
|
Cholesterol crystal embolization presenting as either solid or cystic pancreatic lesion.
|
J Surg Oncol
|
2010
|
0.75
|
|
64
|
Intraoperative Radiotherapy in the Era of Intensive Neoadjuvant Chemotherapy and Chemoradiotherapy for Pancreatic Adenocarcinoma.
|
Am J Clin Oncol
|
2016
|
0.75
|
|
65
|
Predictors of Early Mortality After Surgical Resection of Pancreatic Adenocarcinoma in the Era of Neoadjuvant Treatment.
|
Pancreas
|
2016
|
0.75
|
|
66
|
Multi-Institutional Validation Study of Pancreatic Cyst Fluid Protein Analysis for Prediction of High-Risk Intraductal Papillary Mucinous Neoplasms of the Pancreas.
|
Ann Surg
|
2017
|
0.75
|
|
67
|
Surgical Education and Health Care Reform: Defining the Role and Value of Trainees in an Evolving Medical Landscape.
|
Ann Surg
|
2016
|
0.75
|
|
68
|
A duodenal duplication cyst causing recurrent pancreatitis in a young patient.
|
Am Surg
|
2011
|
0.75
|
|
69
|
Health-related Quality of Life and Functional Outcomes in 5-year Survivors After Pancreaticoduodenectomy.
|
Ann Surg
|
2017
|
0.75
|
|
70
|
Tolerability and Long-term Outcomes of Dose-Painted Neoadjuvant Chemoradiation to Regions of Vessel Involvement in Borderline or Locally Advanced Pancreatic Cancer.
|
Am J Clin Oncol
|
2017
|
0.75
|